ContraFect Announces Additional $2.3 Million in Funding from CARB-X to Support Gram-Negative Lysin Program
January 17, 2019 07:00 ET
|
ContraFect Corporation
YONKERS, N.Y., Jan. 17, 2019 (GLOBE NEWSWIRE) -- ContraFect Corporation (Nasdaq:CFRX), a clinical-stage biotechnology company focused on the discovery and development of protein and antibody...
ContraFect’s Exebacase (CF-301) Improved Clinical Outcomes in Staphylococcus aureus Bacteremia including Right-Sided Endocarditis Compared to Standard of Care Antibiotics Alone in a First-in-Patient Phase 2 Superiority Study
January 07, 2019 07:00 ET
|
ContraFect Corporation
Proof of concept that new class of lysin biologics has the potential to improve treatment outcomes in serious bacterial infections Exebacase demonstrated robust safety and tolerability profile ...
ContraFect to Present at Biotech Showcase 2019
December 20, 2018 17:00 ET
|
ContraFect Corporation
YONKERS, N.Y., Dec. 20, 2018 (GLOBE NEWSWIRE) -- ContraFect Corporation (Nasdaq:CFRX), a clinical-stage biotechnology company focused on the discovery and development of protein and antibody...
ContraFect to Present at Piper Jaffray Health Care Conference
November 19, 2018 07:00 ET
|
ContraFect Corporation
YONKERS, N.Y., Nov. 19, 2018 (GLOBE NEWSWIRE) -- ContraFect Corporation (Nasdaq:CFRX), a clinical-stage biotechnology company focused on the discovery and development of protein and antibody...
ContraFect Appoints Michael Messinger as Chief Financial Officer
November 12, 2018 07:00 ET
|
ContraFect Corporation
YONKERS, N.Y., Nov. 12, 2018 (GLOBE NEWSWIRE) -- ContraFect Corporation (Nasdaq:CFRX), a clinical-stage biotechnology company focused on the discovery and development of protein and antibody...
ContraFect Announces Third Quarter 2018 Financial Results
November 08, 2018 07:00 ET
|
ContraFect Corporation
YONKERS, N.Y., Nov. 08, 2018 (GLOBE NEWSWIRE) -- ContraFect Corporation (Nasdaq:CFRX), a clinical-stage biotechnology company focused on the discovery and development of protein and antibody...
ContraFect to Present at 2nd International Symposium on Antimicrobial Hydrolytic Enzymes
November 01, 2018 07:00 ET
|
ContraFect Corporation
YONKERS, N.Y., Nov. 01, 2018 (GLOBE NEWSWIRE) -- ContraFect Corporation (Nasdaq:CFRX), a clinical-stage biotechnology company focused on the discovery and development of protein and antibody...
ContraFect to Participate in World Antimicrobial Resistance Congress 2018
October 22, 2018 17:00 ET
|
ContraFect Corporation
YONKERS, N.Y., Oct. 22, 2018 (GLOBE NEWSWIRE) -- ContraFect Corporation (Nasdaq:CFRX), a clinical-stage biotechnology company focused on the discovery and development of protein and antibody...
ContraFect to Present at the “Exploring the Antibiotic Pipeline 2018” Symposium and also to Present New Data on CF-301 (exebacase) at IDWeek 2018
September 25, 2018 07:00 ET
|
ContraFect Corporation
YONKERS, N.Y., Sept. 25, 2018 (GLOBE NEWSWIRE) -- ContraFect Corporation (Nasdaq:CFRX), a clinical-stage biotechnology company focused on the discovery and development of protein and antibody...
ContraFect to Present at Two Upcoming Investor Conferences
September 20, 2018 17:00 ET
|
ContraFect Corporation
YONKERS, N.Y., Sept. 20, 2018 (GLOBE NEWSWIRE) -- ContraFect Corporation (Nasdaq:CFRX), a clinical-stage biotechnology company focused on the discovery and development of protein and antibody...